Mindpeak’s PD-L1 CPS AI to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance. Ahead of #PathologyVisions2024 in three weeks, we're excited to share some of our latest findings, also published in Journal of Clinical Oncology. Our study investigated the use of AI-based software to assess PD-L1 expression in gastric cancer. The AI demonstrated a higher agreement with pathologists than pathologists with each other, while classifying more patients as eligible for immunotherapy. Specifically, the AI showed a higher correlation and better concordance (+15%, p<0.05) in classifying patients than pathologists. Overall, the AI detected over 50% more positive cases (46 vs. 30.3), suggesting that the application of AI could help identify more patients eligible for targeted PD-L1 therapy. Thank you Sunil Badve, George L., Tobias Lang, David Mulder, Diego Calvopina, PhD, Patrick Frey, Maria Karasarides, Ph.D. for your contributions and dedicated work. Read more: https://lnkd.in/eKCxxpMV Or meet us at PathVision in Orlando, Florida from November 3-5 at booth #204! #aihealthcare #cancerdiagnosis #digitalpathology #pathology #aihealthcareinnovation
Mindpeak GmbH
IT und Services
Our mission is to enable personalised cancer treatment through AI tissue diagnostics
Info
Mindpeak's mission is to enable personalised cancer treatment through AI tissue diagnostics Our partners are leading pathology and university labs. Our team consists of world-class industry experts in machine learning and company building. Mindpeak's Impact The demand for medical image analysis is growing rapidly but the number of cancer experts remains the same - this results in growing workloads per specialist. We help cancer experts meet this challenge. We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses. This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable. If you want to get in touch with us send us an E-Mail via info@mindpeak.ai.
- Website
-
https://www.mindpeak.ai/
Externer Link zu Mindpeak GmbH
- Branche
- IT und Services
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Hamburg
- Art
- Privatunternehmen
- Gegründet
- 2018
Orte
-
Primär
Zirkusweg 2
Hamburg, 20359, DE
Beschäftigte von Mindpeak GmbH
Updates
-
📣 Welcoming Katja, our new Business Operations Manager! 📣 We are thrilled to announce that Katja Eisele has joined our team as Business Operations Manager. 🎉 Katja brings a remarkable background in operations, project management, and process optimization, with extensive experience in the startup space. Her previous roles include leader and senior positions at VillaCircle GmbH and MYNE, focussing on implementing and streamlining operations, improving efficiency, as well as managing cross-functional teams. With her strong expertise in handling complex projects, fostering team collaboration, and driving growth, we are confident that Katja will make a valuable impact on our ongoing success. Her agile mindset and dedication to achieving scalable, impact-driven solutions align perfectly with our vision. Please join us in welcoming Katja to the team!! We are happy to have you on board! 🙌 #TeamMindpeak #digitalpathology #aihealthcare #biotech #pathology #NewHire
-
Mindpeak GmbH hat dies direkt geteilt
We are excited to announce that Mindpeak GmbH has successfully closed a $15.3 million Series A funding round! This funding was led by ZEISS Ventures and InnoVentureFund (IFB Innovationsstarter GmbH) with participation from - amongst others - AI.FUND and the European Innovation Council Fund. We’re deeply grateful to our investors for their trust and belief in our mission to transform healthcare for the better. https://lnkd.in/exW79XXK This incredible milestone will enable us to accelerate the development of our AI-driven diagnostic solutions, scale our operations, and expand our reach to new global markets 🌍. A special thanks to our amazing team for their exceptional dedication and hard work throughout this journey.
-
We signed our Series A to accelerate our journey with AI in pathology! Kudos to the whole Mindpeak GmbH team!
We are excited to announce that Mindpeak GmbH has successfully closed a $15.3 million Series A funding round! This funding was led by ZEISS Ventures and InnoVentureFund (IFB Innovationsstarter GmbH) with participation from - amongst others - AI.FUND and the European Innovation Council Fund. We’re deeply grateful to our investors for their trust and belief in our mission to transform healthcare for the better. https://lnkd.in/exW79XXK This incredible milestone will enable us to accelerate the development of our AI-driven diagnostic solutions, scale our operations, and expand our reach to new global markets 🌍. A special thanks to our amazing team for their exceptional dedication and hard work throughout this journey.
-
We are excited to announce that Mindpeak GmbH has successfully closed a $15.3 million Series A funding round! This funding was led by ZEISS Ventures and InnoVentureFund (IFB Innovationsstarter GmbH) with participation from - amongst others - AI.FUND and the European Innovation Council Fund. We’re deeply grateful to our investors for their trust and belief in our mission to transform healthcare for the better. https://lnkd.in/exW79XXK This incredible milestone will enable us to accelerate the development of our AI-driven diagnostic solutions, scale our operations, and expand our reach to new global markets 🌍. A special thanks to our amazing team for their exceptional dedication and hard work throughout this journey.
-
We are excited to announce that Mindpeak GmbH has successfully closed a $15.3 million Series A funding round! This funding was led by ZEISS Ventures and InnoVentureFund (IFB Innovationsstarter GmbH) with participation from - amongst others - AI.FUND and the European Innovation Council Fund. We’re deeply grateful to our investors for their trust and belief in our mission to transform healthcare for the better. This incredible milestone will enable us to accelerate the development of our AI-driven diagnostic solutions, scale our operations, and expand our reach to new global markets 🌍. A special thanks to our amazing team for their exceptional dedication and hard work throughout this journey. #AI #HealthcareInnovation #SeriesA #Funding #ArtificialIntelligence #MedicalDiagnostics #Mindpeak https://lnkd.in/exW79XXK
-
📢 Welcoming Christine, our new HR Manager! 📢 We are excited to introduce Christine S. Stamer, who joined our team as HR Manager in June! 🎉 Christine brings a wealth of experience, with over seven years experience at @ Lufthansa Innovation Hub and at Carlsquare. Christine is passionate about fostering the growth of our company and about the team's well-being. She’s committed to building up Mindpeak’s exceptionally high-performing team of the future. If you'd like to connect with Christine in her new role and join us on our mission, check out our current vacancies: https://lnkd.in/ewyytrAg 🔎 (Senior) Backend Developer Python (m/f/d), AI-Based Cancer Diagnostics 🔎 Full-stack Developer Python (m/f/d), AI-based Cancer Diagnostics 🔎 Senior Product Manager (m/f/d) #TeamMindpeak #digitalpathology #aihealthcare #biotech #pathology
-
Training Pathologists in PD-L1 Gastric Assessment with the Help of AI Boosts Diagnostic Concordance #ECP2024 in Florence was a spectacular highlight for the global pathology community. And also for us at Mindpeak GmbH: We were able to present our education platform to train pathologists with the help of AI in evaluating PD-L1 expression in gastric cancer as part of the scientific track. This is the work of a large team of world-class pathologists and leading cancer experts, including Sunil Badve, @Hans-Ulrich Schildhaus, Josef Rüschoff, George L., Maria Karasarides, Ph.D. and many others. PD-L1 assessment in gastric cancer using Combined Positive Scoring (CPS) is among the most challenging tasks in pathology. Previous studies show high interobserver variance. Our results demonstrate that with the help of AI pathologist concordance may increase significantly to excellent diagnostic consistency. Thereby, our AI-based education platform ultimately provides a novel way to achieve better patient outcomes. By the way, if you are at #ESMO2024 in Barcelona, make sure to check out our poster on mutation prediction with multi-modal AI: Sunday, September 15th 2024 → Poster 182 P. #AI #PathologistTraining #GastricCancer #HealthcareInnovation #MedicalAI
-
Thank you so much MD PhD Eugenia Colón for highlighting the impact of AI in pathology! We are proud to see our AI solutions at Mindpeak GmbH contributing to faster, more accurate cancer diagnoses at Sankt Görans Hospital. Empowering pathologists with tools that enhance efficiency and precision is central to our mission. Partnering with exceptional teams at hospitals like Unilabs Sverige, we remain dedicated to equipping healthcare professionals with advanced tools that improve patient care and outcomes.
Yes, digital pathology and AI are showing significant potential in improving diagnostic accuracy and efficiency. At Sankt Görans Hospital Unilabs Sverige Sweden, AI tools like Mindpeak GmbH for breast cancer and Ibex Medical Analytics for prostate cancer are being used to assist pathologists in identifying cancerous cells, speeding up the diagnostic process, and reducing human error. These technologies are not only saving time but also enhancing precision, leading to better patient outcomes. While they won't replace humans, they are powerful tools in improving healthcare delivery.
-
A major highlight for us: Our collaboration with Roche has been featured in the Financial Times! It's so good to see that our joint work is getting so much attention. This recognition is a testament to the dedication and innovation of our entire team at Mindpeak GmbH. It's a significant achievement for us, and we couldn't be prouder of the hard work that has brought us here. A huge thanks to everyone (team, partners, collaborators) who contributed to making this happen, and here's to many more successes to come! Special thanks to David Mulder Tobias Lang Patrick Frey Marc P.Heiko Schmitt Diego Calvopina, PhD https://lnkd.in/dWhkmZx5
Company Announcements
markets.ft.com